11th D2EFT study newsletter

D2EFT: Dolutegravir and Darunavir Evaluation in Adults Failing Therapy Update from a study site: HIV-NAT Thai…

Celebrating the career of a hero of HIV research

From: Kirby Institute The Kirby Institute celebrates the exceptional career of Emeritus Professor Praphan Phanuphak, who…

Looking back at the inception of HIV-NAT in celebration of Professor Praphan Phanuphak’s retirement

Their vision was a cross-cultural HIV research center that would conduct clinical research and intervention studies…

The World congratulates to the result of the research shows that cabotegravir injection is a good way to prevent HIV infection in MSM and Transgender group

After I heard announcement the result of effective injectable cabotegravir to prevent HIV before exposure (PrEP)…

UNAIDS welcomes new tool for HIV prevention for gay men and other men who have sex with men and transgender women

UNAIDS warmly welcomes the announcement that the long-acting injectable cabotegravir is safe and effective in preventing…

COVID-19: What people with HIV should know

Although the risk of serious illness from COVID-19 for people with HIV is not known, people…

Congratulations to our August 2019 PhD graduates

The Kirby Institute would like to congratulate our PhD graduates, Dr Steve Badman and Dr Sasiwimol…

PERSPECTIVES: Are integrase inhibitors the solution to HIV drug resistance in the Asia-Pacific region?

We asked four regional clinicians, researchers, and policy makers to share their reflections on whether integrase…

Dolutegravir: A Key HIV Drug That Too Many People Cannot Get

The integrase inhibitor dolutegravir (DTG) has shown great promise as a medicine to treat HIV since…

United Nations Under-Secretary-General and UNAIDS Executive Director Michel Sidibé visits her Royal Highness Princess Soamsawali of Thailand at Chulalongkorn Hospital

Bangkok, Thailand, 1 May 2019: United Nations Under-Secretary-General and UNAIDS Executive Director Michel Sidibé who was…